The only manufacturer of integrated-capability of oligos & monomer in the global market
Nucleoside Monomer
Protected Nucleosides
Phosphoramidites
Oligonucleotide
- asiRNA/microRNA
- bAntisense
- cAptamer
- dDecoys
- eOther novel oligos
CDMO
Oligonucleotide & Monomer
Oligonucleotide & Monomers CDMO
- 1Global top-3 positioned service
- 2Fully Integrated capability
- 3Sugars, Nucleosides to Phosphoramidites
Monomer CDMO
Innovative manufacturing system & platform- Supplied nucleoside-API's for global pharma since 1980’s
- The first production of oligo based on GMP in 2008
- World’s only monomer/oligo “one-stop” manufacturing system
- Excellent experiences with global pharma & quality system
- Supplied nucleoside-API's for global pharma since 1980’s
- The first production of oligo based on GMP in 2008
- World’s only monomer/oligo “one-stop” manufacturing system
- Excellent experiences with global pharma & quality system
ST PHARM's Oligonucleotide CDMO
The seamless CDMO Service from Monomer to Oligonucleotide
Demonstrated the superiority of global level-oligo CDMO business
Strong track record- Well-established tech transfer and scale up production with 15 years experience for over 20 GMP oligos manufactured including Phase III and commercialized uses for US and Europe clients
- Selected as Asia-Pacific’s Top Oligonucleotide API Manufacturer and Korea’s first company to be awarded with ‘2018 Global API Manufacturing (Oligonucleotide) Growth Excellence Leadership Award’ from Frost & Sullivan
- Roche CDMO Award 2019 : Oligo New Drug (First in global), Small Molecule New Drug (First in Asia)
- Well-established tech transfer and scale up production with 15 years experience for over 20 GMP oligos manufactured including Phase III and commercialized uses for US and Europe clients
- Selected as Asia-Pacific’s Top Oligonucleotide API Manufacturer and Korea’s first company to be awarded with ‘2018 Global API Manufacturing (Oligonucleotide) Growth Excellence Leadership Award’ from Frost & Sullivan
- Roche CDMO Award 2019 : Oligo New Drug (First in global), Small Molecule New Drug (First in Asia)
Facility & Capacity (Oligo Plant)
Capacity (Oligonucleotide)
Oligonucleotide
Sihwa
Banwol
Note
R&D Facility
(4mmol scale) × 4
DOE study
low dose clinical
low dose clinical
Pilot Plant
(200mmol scale) × 2
Large-scale Plant
6.4 mole scale (2022)
10.2 mole scale (2024)
14.0 mole scale (2026)
(Expansion, on going)
10.2 mole scale (2024)
14.0 mole scale (2026)
(Expansion, on going)
Clinical or Commercial
(Low volume)
(Low volume)
Sihwa Campus
Oligo R&D Center
Oligo Pilot Plant
Banwol Campus
Oligo the 1st Plant
(Commercial scale)
the 2nd Oligo Plant